The company's pipeline focuses on acute organ traumas, vascular damage, and cancer immunotherapy, and is based on the receptors involved in regulating immune response in oncology and organ damage. Clevegen is an investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumors. Traumakine is an investigational intravenous interferon beta-1a, a strong anti-viral and anti-inflammatory agent, currently being tested in several Phase III studies around the world against COVID-19. Faron is based in Turku, Finland, and listed on AIM under the ticker ‘FARN’ and Nasdaq First North Growth Market under ticker FARON.